Grapiprant, also known as AT-001 and CJ-023, is a drug from the piprant class. These molecules were derived from acylsulfonamide and are characterized to be a novel series of para-N-acylaminomethylbenzoic... This type of molecules is currently in development for veterinary patients.
- Mechanism
- Curator reviewed · 3 references
Grapiprant is an EP4 prostaglandin receptor antagonist and thus the activity of this drug is thought to be completely related to the selective blockade of this receptor. It binds to human and other mammals EP4 prostaglandin receptor with high affinity without interfering with other prostaglandin pathways which are important for a variety of physiological functions. The binding of grapiprant blocks PGE2 binding and hence its biological effect related to the signaling pain and inflammation cascade.
Grapiprant has been accepted very greatly in veterinary as its mechanism of action is a targeted approach to pain management by not having any interaction with the production of prostanoids and thus, by not interacting with other prostaglandin receptor pathways.
- Primary indication
- The effects of grapiprant have been investigated in the area of analgesia and anti-inflammation due to the effects that have been reported about this molecule.Curator reviewed
- Formula / weight
- C26H29N5O3S · 491.61 g/mol (avg)
- Code names
- AAT-007 · AT 001 · CJ-023,423 · MR-10A7 · RQ-00000007
Resolves to
HZVLFTCYCLXTGV-UHFFFAOYSA-NSMILESCCC1=NC2=C(C)N=C(C)C=C2N1C1=CC=C(CCNC(=O)NS(=O)(=O)C2=CC=C(C)C=C2)C=C1What you can answer from here — as of September 23, 2026
Which drugs share a target with Grapiprant, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account